Shukra Pharmaceuticals Approves Object Clause Amendment and Name Change to Shukra Medtech
Shukra Pharmaceuticals Limited shareholders approved a name change to Shukra Medtech Limited and an amendment to the object clause of the Memorandum of Association via remote e-voting. Both resolutions passed with over 99.9% of votes in favor. The voting concluded on September 26, 2026.
The name change to 'Shukra Medtech Limited' and the amendment to the object clause are significant corporate actions that could signal a strategic shift or expansion in the company's business focus, potentially impacting its future operations and market perception.
The resolutions were passed with a very high majority, indicating strong shareholder approval for the company's proposed changes, including the name change and amendment to its object clause.
Shukra Pharmaceuticals Limited has announced the results of its postal ballot voting, conducted entirely through remote e-voting. The voting period concluded on September 26, 2026.
The shareholders approved two key resolutions. The first resolution, an ordinary resolution, concerned the amendment of the object clause in the company's Memorandum of Association. This resolution received overwhelming support, with approximately 99.97% of the valid votes cast in favor.
The second resolution, a special resolution, involved changing the company's name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited'. This name change also necessitates consequent amendments to the Memorandum and Articles of Association. This resolution was also passed with a significant majority, with approximately 99.96% of the valid votes cast in favor.
Both resolutions were deemed to have passed on September 26, 2026, the last day for remote e-voting. The Scrutinizer's Report, dated September 29, 2026, confirms the results. The company's Managing Director, Dakshesh Shah, has signed off on the announcement.
What to do with a filing like this
Shukra Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under shareholder meetings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shukra Pharmaceuticals Limited. Read the original for the full detail.